Positive capsules enter phase II clinical in the United States

July 23 in Shanghai, "
Chinese medicineinternationalization" summit forum, by the ShanghaiOf Chinese MedicineUniversity of Liver Disease Research Institute, Shanghai ModernChinese MedicineTechnology Development Co., Ltdand other jointly developed anti-liver fibrosis new drug - positive capsules (tablets), approved in the United States to enter the second phase of clinical researchThe second phase of clinical trials on positive capsules (tablets) was conducted against hepatitis CThe Second Phase II clinical study of hepatitis C approved by the U.SFoodDrugAdministration (FDA) will be completed in 2009 and 120 U.Spatients with hepatitis C will be clinically treated"This is the first new drug in the U.Sto be approved by the FDA and into Phase II clinical studies without any discussion," said Professor Hassani, director of the Center for Hepatology and Liver Transplantation at the University of California, San Diego School of Medicineaccording to, the number of people infected with HCV worldwide is as high as 170 million, and there are 5 million hepatitis C patients in the United States alone, of which 20% of the virus-type C can develop cirrhosisIn the face of refracted hepatitis C, the existing drug is only interferon one, and 50% of patients are insensitive to the drug, so the search for an effective treatment for hepatitis C has become a common task of liver disease specialists worldwideThrough the clinical treatment of more than 50,000 cases, the positive chemical capsule (tablet) has proved that it has a unique effect on the treatment of chronic hepatitis B and cirrhosis, and won the second prize of national scientific and technological progress in 2003, and entered the national medical insurance drug catalogue